
        <!DOCTYPE html>
        <html>
        <head>
            <title>Biogen Inc. (BIIB) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Biogen Inc. (BIIB)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">49</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">27</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">6</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">0.30</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f3671c7f3a07cee82a64ae475449a01e859980b9d35f84dbd4738947b78cb331" target="_blank" rel="noopener noreferrer">Here's What to Expect From Biogen's Next Earnings Report</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.59
                                </span>
                            </div>
                            <div class="article-summary">Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=a79f2aa84b20a7ee359607387f4d7e0522d62c1156ab32fc37c7b11e52672ff1" target="_blank" rel="noopener noreferrer">Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-18</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.58
                                </span>
                            </div>
                            <div class="article-summary">A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=5062ad2118d41e98ac0b6f0ab7e0197b6bde1b0c1cdf74a11f3f48b8ed5d9071" target="_blank" rel="noopener noreferrer">Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-17</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.73
                                </span>
                            </div>
                            <div class="article-summary">INCHEON, Korea, July 17, 2025--Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=bd7c73d9a085d7a907dc288c201c9220699f395b83793b18a2c15d9cc262531c" target="_blank" rel="noopener noreferrer">Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-17</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.88
                                </span>
                            </div>
                            <div class="article-summary">NASHVILLE, July 17, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=293b97a7cae54e8e78b0c149f7e80e6f625aa2938d80e20cd9dd849e83778a39" target="_blank" rel="noopener noreferrer">The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-16</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.89
                                </span>
                            </div>
                            <div class="article-summary">BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's disea...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=cb0b56daaf668d75e90470e4d439c0e843a6615f148fefabf85074f7ee81ecdc" target="_blank" rel="noopener noreferrer">Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-15</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Douglas E. Williams, Ph.D. Chair of the Board of Directors Strong track record at executive and board level of building company value across all stages of development including supporting the developm...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=0285ff261bc9b409d38e02fd93bbec9707a81d2537ef538062e90561e79e5b68" target="_blank" rel="noopener noreferrer">Biogen Inc. stock underperforms Tuesday when compared to competitors</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-15</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment negative">
                                    -0.90
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock underperforms Tuesday when compared to competitors...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8a3ebb749ed8432b74e439e74819c73062f0ad18efc354d45d7226c829450eca" target="_blank" rel="noopener noreferrer">Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 | Increase in Clinical Trials and Investments will Accelerate the Development of Innovative Treatments</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-14</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.75
                                </span>
                            </div>
                            <div class="article-summary">The ALS market is witnessing robust growth driven by increased disease awareness, advancements in genetic research, and an expanding pipeline of therapeutic drugs. ALS, a neurodegenerative disease aff...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ed6b3e9c41c0c4097ff67891dd2e8c7caf7cf443c0fb78ffe110c1c84137ab35" target="_blank" rel="noopener noreferrer">Why Novartis Is Still A 'Buy' After 15% Surge</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-13</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.37
                                </span>
                            </div>
                            <div class="article-summary">Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d865c91a71641dde5c43cd76de6c0a10f08334174afe2cecf528161a1612ab6b" target="_blank" rel="noopener noreferrer">Patient Capital Management Q2 2025 Investment Review</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-13</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">nan...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2a9deb6742e45552bbbbddc4dc2a16a7bf439ff9790bdabce9967547b739fbfa" target="_blank" rel="noopener noreferrer">Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Barclays upgraded the company’s stock to “Overweight” from “Equal Weight” wit...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e78da2ce431b58e52329cf08a3b757f34971eafabfed5f3792a78b5720949952" target="_blank" rel="noopener noreferrer">Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.37
                                </span>
                            </div>
                            <div class="article-summary">– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the in...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4d994501e0e688984803a3cb1ba3bd12f30c5e488b78383ffe1343a5946ff519" target="_blank" rel="noopener noreferrer">Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">BEDFORD, Mass., & CAMBRIDGE, Mass., July 10, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RN...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=929f97c6bdcdd4fa431bb3d4412d41a8d45eed1de58551371d292a056251e790" target="_blank" rel="noopener noreferrer">RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.52
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (N...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=42efe049fd0570e714508ece3f6c6d5d2f7583cbc169de2f6e97342e6421a0dd" target="_blank" rel="noopener noreferrer">Biogen Inc. stock outperforms competitors on strong trading day</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-10</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment positive">
                                    0.94
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. stock outperforms competitors on strong trading day...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d84c62315f787a10c240290d27b94089bb9068a43581f030d65a81770747f2e8" target="_blank" rel="noopener noreferrer">US FDA approves gradual dosing for Lilly Alzheimer's drug</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-09</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">The U.S. Food and Drug Administrationapproved changing the prescribing information for Eli Lilly'sAlzheimer's drug Kisunla to allow more gradual dosing tolower the risk of a potentially dangerous......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=1483c8a951161335aa0d8e77aa67301597654a341db15f76c721977cdbb4a6ff" target="_blank" rel="noopener noreferrer">DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-08</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.56
                                </span>
                            </div>
                            <div class="article-summary">Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=490cbd256164b31c17b2d147842dbee8f8f1f1bf7a22a444c4aeb21566e7d96c" target="_blank" rel="noopener noreferrer">Biogen Expects $46M 2Q Expense From In-Process Research and Development</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-07</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen Expects $46M 2Q Expense From In-Process Research and Development...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2606d029d00c63211b437f9ce0c044abe459c0b4a972802a7a61ebb77e7f6d43" target="_blank" rel="noopener noreferrer">Biogen estimated charge to impact eps by ($0.26) per share for q2</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-07</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment negative">
                                    -0.30
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc:Biogen Inc - estimated charge to impact eps by per share for q2 - SEC filingBiogen Inc - expects $46 million expense for bought research and development in q2 2025 - SEC filing......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=76d38852d004544646e52b90fa07e427e070b22a9b207e1f6ab953f732d134dd" target="_blank" rel="noopener noreferrer">Biogen : Preliminary Q2 2025 Acquired IPRD & Licensing Income</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-07</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">‌UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e901e538d15fcecb5b53608674d9c74a9fdbcaa69ed28869e8c49e767e2bec68" target="_blank" rel="noopener noreferrer">Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.93
                                </span>
                            </div>
                            <div class="article-summary">Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the ...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=eddb1804046442fce8fc81ada6ac4ce666824a7b09ee5f5330ba099ad06954c0" target="_blank" rel="noopener noreferrer">3 Reasons BIIB is Risky and 1 Stock to Buy Instead</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.58
                                </span>
                            </div>
                            <div class="article-summary">Over the past six months, Biogen’s stock price fell to $125.58. Shareholders have lost 16.3% of their capital, which is disappointing considering the S&P 500 has climbed by 5.7%. This might have inves...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=065d3bd2b2359a15da5b3d0762f8a615d917683cc0f0ac3781c6d23a179a7c2f" target="_blank" rel="noopener noreferrer">Biogen Begins Phase III Felzartamab Study for Third Kidney Disease</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-07-01</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.38
                                </span>
                            </div>
                            <div class="article-summary">BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=613797cf2a3098fea66d75d1e072cfce3882c65d38d69219415f36d98b7aee71" target="_blank" rel="noopener noreferrer">Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment positive">
                                    0.64
                                </span>
                            </div>
                            <div class="article-summary">Biogen Launches Phase 3 Study of Felzartamab in Rare Kidney Disease PMN...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b379302d6de81f621e3c126694bf877871f310569635559ea6ab59e1ae6c66b4" target="_blank" rel="noopener noreferrer">Biogen Inc.(NasdaqGS: BIIB) added to Russell 1000 Defensive Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. added to Russell 1000 Defensive Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=616e996e9017aa0853683e18d7569f51801d799b96336df19f98f4d51d833135" target="_blank" rel="noopener noreferrer">Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies spec...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=aa3fd58b3af4e34e4d99f93669cc36a6924b778285e9f813fadfcf28a283837d" target="_blank" rel="noopener noreferrer">RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.89
                                </span>
                            </div>
                            <div class="article-summary">Investing.com -- RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pav...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=1ae7614f475c00531f3dbe2acbf715de5078e4f06d6d3394596db612a35b334f" target="_blank" rel="noopener noreferrer">AbbVie to buy Capstan for up to $2.1 billion in immunology push</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.51
                                </span>
                            </div>
                            <div class="article-summary">(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatm...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=bac0270fc1de8e13b851d6489d29ff73601c38b92c3a806b4ae7dbd818ae1284" target="_blank" rel="noopener noreferrer">Biogen Inc.(NasdaqGS: BIIB) added to Russell 1000 Value-Defensive Index</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.62
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. added to Russell 1000 Value-Defensive Index......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=45e7283659a02c97a0616cca407ed56f0cbdc445e71df4a0202448c9c4b171c7" target="_blank" rel="noopener noreferrer">Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.71
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7aa0460938b178cfe7ff3a271ec592aa31557e2ed62c6a983953884d2ed0e41b" target="_blank" rel="noopener noreferrer">BIOGEN : TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS JULY 31, 2025</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-30</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Cambridge, Mass.- Biogen Inc. today announced it will report second quarter 2025 financial results Thursday, July 31, 2025, before the financial markets open. Following the......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f8b841b49e467eedbb83f8658fce9de0cf506867c295a73ef82f62f1a87c5e35" target="_blank" rel="noopener noreferrer">S&P 500 Stocks: Screening For Long-Term Winners, My List Of 13</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-29</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">A shift away from big tech dominance is fueling interest in under-the-radar S&P 500 stocks with alpha potential. Find out why stock-picking is making a comeback....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=b4312990b1e53f7e6820b12d9eebefd419acdb918ad558314580b421c8ed6686" target="_blank" rel="noopener noreferrer">Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-28</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.92
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for salane...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=1750506322093600e8cc302d3c220d7c1b3877871c0499e2efe8d3ffe37e6f9b" target="_blank" rel="noopener noreferrer">Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-28</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.38
                                </span>
                            </div>
                            <div class="article-summary">Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e9fc244962285d27818551b0bf6a2b038f7a2927fe78cc084d3021ebc8108a4c" target="_blank" rel="noopener noreferrer">New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.37
                                </span>
                            </div>
                            <div class="article-summary">New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=c30a809f024a3f93f766f041a7bce74afa24d0c824855a850b368803e524aee5" target="_blank" rel="noopener noreferrer">Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-27</span>
                                <span>Finnhub</span>
                                <span class="article-sentiment positive">
                                    0.72
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy . These latest findings from Part C of the......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=91cfff372e8aa4a887791999919b3430d59aacec39f289b1840fba9db369024a" target="_blank" rel="noopener noreferrer">5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-26</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.57
                                </span>
                            </div>
                            <div class="article-summary">Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management highlighted the expanding contribution from its newer neurology and rare disease pr...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=f5cab6aadc4cc476ee8796607671730907ad5e7bb681e1cfd33176010cb1b7d4" target="_blank" rel="noopener noreferrer">Denali Therapeutics: Navigating Through Recent Setbacks</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-26</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">nan...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ef90bcf2c6477c2e9aebc81fc96aa58764f7a1305ae955963929efc03e676210" target="_blank" rel="noopener noreferrer">Biogen to Advance SMA Treatment Into Registrational Studies</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>MarketWatch</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen to Advance SMA Treatment Into Registrational Studies...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=434516bd824c3d1076c26cb9d25c6f392bd42be9a1308427eb71bf5171300774" target="_blank" rel="noopener noreferrer">Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.54
                                </span>
                            </div>
                            <div class="article-summary">Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show chil...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=d8112563459e015b2d757bf76ca532f1ea8b33aa7276e63e0d5354366c7fcae1" target="_blank" rel="noopener noreferrer">Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.76
                                </span>
                            </div>
                            <div class="article-summary">CARLSBAD, Calif., June 25, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB1...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=5933734a69830cc0d0d61813206e32f1c564b53a9e30255180dc0f7c77c7dafd" target="_blank" rel="noopener noreferrer">Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.88
                                </span>
                            </div>
                            <div class="article-summary">The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleot...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=3ab045e092b45b0a4b548c147855fbcd14317e2a66dae30a08b22078ec71f156" target="_blank" rel="noopener noreferrer">Can Biogen Save Even More Kids With This New Drug?</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>DowJones</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Can Biogen Save Even More Kids With This New Drug?...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=8ce3d1fe66b61efebbbe8331394b083fa223a2085fb3356e3cdd574143eb28d1" target="_blank" rel="noopener noreferrer">Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-25</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.83
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a prominent contender at the Cannes Lions International Festival of Creativity ...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4569d36647df4301c694aba83afa2c3e48e6cdf2a6d6709978ea28d34091e4c6" target="_blank" rel="noopener noreferrer">Biogen scores Cannes Festival win with dark humored campaign</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-24</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.67
                                </span>
                            </div>
                            <div class="article-summary">The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=931ed0b7e78a6f314c4ca0c78207bae003bbc81608ddccc0057aeef54e90e903" target="_blank" rel="noopener noreferrer">Biogen: Investors Are Missing The Bigger Picture</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-23</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment negative">
                                    -0.37
                                </span>
                            </div>
                            <div class="article-summary">Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. Read more on BIIB stock here....</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ead721171471cd8070bcc12bb663b8afd49c83bdbaa0a947f175adb45797394a" target="_blank" rel="noopener noreferrer">Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-23</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Biogen Inc. (NASDAQ:BIIB) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has begun dosing in the global Phase 3 BRAVE trial to test omaveloxolone (SKYCLARYS®) in children age...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=aca5d67fcbd0f3286119150b0f26ab33f9526dae16eaeee9b4c29282c07e7864" target="_blank" rel="noopener noreferrer">Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice preside...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=e9479e4add711224ea8bea7f18235d31ab0d90d0cfbd714f3fa974dbf498ffcb" target="_blank" rel="noopener noreferrer">Biogen starts dosing in Phase III trial of Friedreich ataxia therapy</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects....</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        